Special Issue "Respiratory Immune Responses during Infection and Pollution Inhalation"
Deadline for manuscript submissions: 30 November 2021.
Interests: pulmonary diseases; phosphatases; immunology; innate responses; cigarette smoke exposure; chronic obstructive pulmonary disease; alpha-1 antitrypsin deficiency; viral exacerbations; allergy; damage-associated molecular patterns
Interests: pulmonary diseases; pulmonary biology; rare lung disease; lymphangioleiomyomatosis; pulmonary alveolar proteinosis; alpha-1 antitrypsin deficiency; glycosylation of acute phase proteins; macrophages; lipid dysfunction; cholesterol homeostasis
The current COVID-19 pandemic highlights the importance of lung immune responses to pathogens and environmental factors. The lungs and upper airways are typically the first site of exposure to external factors and are exposed to over seven thousand liters of air per day. In response to harmful organisms and toxic pollutants, the lungs have a comprehensive and complex system of resident and immune cells with innate and adaptive immune responses. Altered immune responses can impact the primary role of the lungs, i.e., gas exchange. Resolution of altered immune responses is critical for normal lung function. A wide variety of cellular responses are altered due to inflammation responses that are associated with alteration of lung physiology and function. Within the lung, there is a complex interplay between resident cells, infiltrating immune cells, a multifaceted microbiome, a mucus clearing system, and secreted immune proteins that shape the outcome of host–pathogen, host–allergen, and host–particle interactions within the lungs. Pre-existing conditions and inhalation of noxious factors will alter these interactions and immune responses upon infection and/or prevent the restoration of homeostasis within the lungs. This research topic aims to collect recent updates and novel findings to elucidate important immune changes that occur within the lungs during an infection or following exposure to noxious factors. We are inviting original research articles, reviews, mini-reviews, and methods addressing immune responses in healthy lungs or pre-existing lung diseases during an infection or following exposure to noxious compounds.
Dr. Patrick Geraghty
Dr. Cormac McCarthy
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lung disease